JDL(SH:688057) Zheng Quan Ri Bao Wang·2025-12-20 03:56Group 1 - The core point of the article is that Jiangxi Jindalai Environmental Protection Co., Ltd. plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake, driven by optimism about the development prospects of stem cell technology and its applications [1][3] - Jindalai aims to optimize its industrial structure and seek new growth opportunities to enhance its risk resistance and cultivate new profit growth points through investments in strategic emerging industries like biomanufacturing and health care [3][4] Group 2 - Jindalai is recognized as an advanced innovative comprehensive service provider for water environment governance, with its main products and services including water pollution control equipment and overall solutions for water environment [2] - The company's FMBR wastewater treatment system is characterized by simplicity, originality, and modernization, offering significant advantages over traditional wastewater treatment methods, such as reduced sludge volume and lower comprehensive costs [2] - Jici Medical specializes in the research and application of autologous cell technology, holding unique advantages in the field of cell reprogramming and rejuvenation, with a series of patented technologies for developing various functional cells [4][6] Group 3 - Jici Medical has developed an autologous rFib injection that has been tested for safety and efficacy across over 30 clinical indications, with plans to enter the pre-IND stage for some products [5][6] - The company has established multiple research platforms in collaboration with various institutions to promote technology transfer and high-end talent cultivation [5][6] - As of September 30, 2025, Jici Medical reported total assets of 10.01 million yuan, with revenues and net profits of 11.23 million yuan and 1.15 million yuan respectively, indicating a modest performance due to limited funding and small operational scale [6]